



Mapping HTA structures and processes in the Member States

Knowledge for cooperation

Flora Giorgio

Kristina York

HTA Mapping - WHY

- *Useful for Member States in the process of setting up HTA capacity and strengthening it*
- *Useful for all to ease cooperation at EU level*
 - **By identifying key stakeholders and their roles**
 - **Keeping track of evolving legal framework**



HTA Network minutes 29 October 2014

HTA Mapping – WHAT (I)

- *Reviewed existing material, including EUnetHTA and other sources*
 - **→ many changes in the last 2-4 years**
- *Set out definitions and identify a template to collect and present information applicable to the majority of countries*
- *Started small*
 - **→ sample of MSs (small, medium, large), so far ES, BE, DK, FI, FR, DE, IT, NL, PL, SE, UK (11MS)**
 - **→ 9 MS volunteered to fill in a simple form**

HTA Mapping – WHAT (III)

| Technology | Licensing | HTA | | | Decision uptake | | |
|---------------------------|-----------|------------|-----------|--------------------|-----------------|---------|-----|
| | | Assessment | Appraisal | Cost-effectiveness | Reimbursement | Pricing | Use |
| Medicines | | | | | | | |
| Medical devices | | | | | | | |
| Other technologies | | | | | | | |

Preliminary observations

HTA process:

- **Single body for assessment and appraisal in 7 out of 11 countries;**
- **Single body for licencing and HTA for medicines found in 3**

Reimbursement:

- **Final decision by Ministry of Health based on national HTA reports - different in countries where regions allocate budgets**

Preliminary observations on reimbursement: National vs. Regional competence

In some MS national **HTA recommendations** for reimbursement are **not legally binding**, sometimes leading to the regions having the final say citing budgetary reasons.

Value measures differ between Member States and even between regions in one country

HTA Mapping form for Member States

| | | | | |
|---|-------------------------|------------------------|-----------------------|---------------------------|
| COUNTRY: | SCOPE: Medicines | | | |
| Netherlands | | | | |
| | Licencing BODY | HTA | | Reimbursement BODY |
| | | Assessment BODY | Appraisal BODY | |
| CBG-MEB Medicines evaluation Board | ZIN | ZIN | Ministry of Health | |

| | | | | |
|-----------------------------------|-------------------------------|------------------------|-----------------------|---------------------------|
| COUNTRY: | SCOPE: Medical devices | | | |
| Netherlands | | | | |
| | Licencing BODY | HTA | | Reimbursement BODY |
| | | Assessment BODY | Appraisal BODY | |
| Dekra Certification BV | ZIN | ZIN | Ministry of Health | |

HTA Mapping – Next steps

- *HTA Network feedback on the templates and definitions*
- *Secretariat will amend and populate template based on most recent information*
- *HTA Network to validate the information*
- *Target timeline : end of 2015*

Thank You for your attention!

Special thanks to WG members
responding to the survey